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A Patient Diagnosed with Spinocerebellar Ataxia Type 5 
associated with SPTBN2: Case Report
Spinocerebellar ataxias (SCAs) are autosomal dominant neurodegenerative disorders 
which disrupt the afferent and efferent pathways of the cerebellum that cause 
cerebellar ataxia. Spectrin beta non-erythrocytic 2 (SPTBN2) gene encodes the β-III 
spectrin protein with high expression in Purkinje cells that is involved in excitatory 
glutamate signaling through stabilization of the glutamate transporter, and its 
mutation is known to cause spinocerebellar ataxia type 5. Three years and 5 months 
old boy with delayed development showed leukodystrophy and cerebellar atrophy 
in brain magnetic resonance imaging (MRI). Diagnostic exome sequencing revealed 
that the patient has heterozygous mutation in SPTBN2 (p.Glu1251Gln) which is 
a causative genetic mutation for spinocerebellar ataxia type 5. With the patient’s 
clinical findings, it seems reasonable to conclude that p.Glu1251Gln mutation of 
SPTBN2 gene caused spinocerebellar ataxia type 5 in this patient.
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Introduction
Spinocerebellar ataxias (SCAs) are a clinically heterogeneous group of 
autosomal dominant neurodegenerative disorders that cause cerebellar ataxia by 
disrupting the afferent and efferent pathways of the cerebellum1). The typical age 
of onset is between the 30s and 40s, and presentation can be with different 
clinical symptoms. Consequently, more than 30 types of SCA have been 
described so far2). There are three major classes of SCA. A first category includes 
SCA caused by CAG repeat expansions. A second category contains the SCA 
which are due to repeat expansions of the respective disease genes. A third 
category is SCA caused by conventional mutations in specific genes like missense 
and deletions. SCA5 belongs to third category of SCAs3).      
In 2006, heterozygous mutations in the spectrin beta non-erythrocytic 2 gene 
(SPTBN2), which encodes β-III spectrin, were found to cause spinocerebellar 
ataxia type 5 (SCA5)4). The expression of SPTBN2 is particularly high in the 
Purkinje cells involved in excitatory glutamate signaling through stabilization of 
the glutamate transporter. SCA5 has a prevalence of <1% and is a rare cause of 
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ataxia5). Although SCA5 is characterized by pure cerebellar 
symptoms, with over 90% of affected individuals primarily 
exhibiting limb and gait ataxia, other features may occur6). 
Indeed, dysarthria, sensory deficits, truncal ataxia, abnormal eye 
movements, and hyperactive deep tendon reflexes are present 
in 25%–90% of patients7). In this case report, we present the 
details of a male patient diagnosed with SCA5 caused by a novel 
heterozygous mutation in SPTBN2 (p.Glu1251Gln). 
Case report
The patient was three years and 5 months old when he was 
brought to our clinic with the chief complaint of developmental 
delay. The patient’s height was 91 cm (50-75 percentile) and 
weighted 14 kg (50-75 percentile) without dysmorphism when 
he visited our clinic. He was born by cesarean section at 
gestational age of 39 weeks, weighing 2.98 kg, and his perinatal 
history was unremarkable. Also he had no specific family 
history. Patient’s parents had genetic test which showed no 
genetic mutation. An investigation of his developmental history 
revealed that he gained control over his head movements at 3 
months and could roll over at 4–5 months of age. His parents 
noticed motor developmental delay at the age by which he 
should have learnt to stand/walk. When we had physical 
examination, he did not show pyramidal sign or extrapyramidal 
sign. His muscle tone in proximal part was hypotonic. He 
eventually stood up at 15 months and started walking 20 months 
of age. Also we have done eye examination which showed 
normal. To evaluate delayed development, he was tested using 
the Bayley developmental scale, and the results revealed that he 
had mental development equivalent to that of a 20-month-old 
child and motor development equivalent to that of a 15-month-
old child. Both results were below the 0.1 percentile for his age 
group. At the most recent assessment, he could walk indepen-
dently, but did so with an unstable wide-based gait. He could 
talk three to four words sentences. Results of chromosome 
analysis, metabolic work-up, genetic study for proteolipid 
protein 1, and other general laboratory examinations performed 
at other hospitals were normal. However, leukodystrophy and 
mild cerebellar atrophy were identified on a brain magnetic 
resonance imaging (MRI) scan, performed one year before 
visiting our clinic, and when we repeated the MRI scan, we 
noted progression of the leukodystrophy but no change in the 
mild cerebellar atrophy (Fig. 1). Based on the lack of a clear 
clinical diagnosis and our suspicion of an underlying genetic 
disorder due to delayed development, gait disturbance, and 
cerebellar atrophy in brain MRI, diagnostic whole exome 
sequencing was performed.
The result revealed a novel heterozygous mutation in SPTBN2 
(p.Glu1251Gln), which was considered compatible with the 
causative mutation in SCA5 (Fig. 2). Sanger sequencing was 
performed to confirm the genetic disorder. At present, the 
patient is undergoing regular physical therapy and treatment 
with dantrolene, which have improved the muscle spasticity in 
his legs.
Discussion
In this report, we have presented a case of SCA associated 
with a mutation in the SPTBN2 gene. SCA5 is a human neurode-
(A) (B)
Fig. 1. (A) The bilateral symmetrical diffuse T2 high signal intensity at the cerebral white matters, including 
both subcortical U-fibers and periventricular white matter (T2 FLAIR axial image), (B) mild cerebellar atrophy.
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generative disorder that causes gait ataxia, slurred speech, vision 
abnormalities, and loss of coordinated movement of the 
extremities6). In some cases, patients can develop pyramidal or 
extrapyramidal signs, ophthalmoplegia, or cognitive impair-
ment11). However, the typical age of onset is between the 30s 
and 40s, with the disease restricted to neurodegeneration of the 
cerebellum. SCA5 has a variable age of onset and slow disease 
progression. Childhood onset is associated with a more severe 
course, purely cerebellar clinical features, predominant Purkinje 
cell loss, and global cerebellar atrophy. In this case, onset age is 
young which lead to more severe course, but active rehabilita-
tion can minimize functional loss in patient. Therefore, unknown 
cerebellar ataxia or cerebellar atrophy should consider 
diagnostic whole exome sequencing irrespective of onset age.
SCA5 is an autosomal dominant disease caused by mutations 
in the SPTBN2 gene that encodes β-III spectrin. The highest 
expression of β-III spectrin is in the Purkinje cells of the 
cerebellum8). At the surface of the plasma membrane in Purkinje 
cells, SPTBN2 stabilizes Excitatory Amino Acid Transporter 4 
(EAAT4)11). Although it is known that the product of the mutant 
gene fails to stabilize EAAT4 at the plasma membrane, which 
adversely affects the glutamate signaling pathway9), it is still 
unclear how mutations in β-III-spectrin cause Purkinje cell 
death in patients with SCA5. Some evidence has led to the 
proposal that SCA5 results from the destabilization of specialized 
synaptic membrane domains or defects in intracellular 
transport10). Another possible pathogenic mechanisms of SCA5-
associated mutations include transcriptional dysregulation and 
impaired protein degradation.
In the present case, the patient had significant developmental 
delay and gait disturbance. However, symptoms can lead to 
considerable functional declines in physical and social activities. 
Given that the disease will progress throughout the life, further 
assessment is indispensable. Following the patient’s progression 
would facilitate the initiation of symptom-targeting therapies, 
including medication, physical therapy, and rehabilitation, as 
required to minimize functional loss.  
This patient presented with delayed development and gait 
disturbance, and an MRI scan of his brain revealed cerebellar 
atrophy and progressive leukodystrophy. Whole exome 
sequencing revealed a missense mutation (p.Glu1251Gln) in the 
SPTBN2 gene on chromosome 11. Three mutations in this gene 
are known to cause SCA5; these comprise one missense 
mutation that interferes with the actin binding site in the second 
calponin homology domain (p.L253P) and 2 deletions (p.E532_
M544del and p.L629_R634delinsW) within the third SPEC 
domain of the protein that are believed to disrupt the triple 
alpha-helical structure of the repeats7). Although there are no 
previous reports of the p.Glu1251Gln mutation causing SCA5, 
given this patient’s clinical findings, it is reasonable to conclude 
that it was causative in this case. 
In conclusion, cerebellar dysfunction is the primary characte-
ristic of SCA, but it can also be associated with various other 
clinical features. Brain MRI scanning is essential in identifying 
cerebellar atrophy, while diagnostic whole exome sequencing 
can be helpful in diagnosis with typical symptoms when other 
causes of cerebellar ataxia cannot be ruled out. Further genetic 
studies are required to clarify the role of the identified genes in 
SCA
요약
척수소뇌실조는 임상적으로 다양하게 나타나는 보통염색체 우성 
신경변성 (혹은 퇴행성) 질환군으로서, 소뇌의 들과 날의 경로를 분열
시켜 소뇌 실조를 일으키는 것으로 알려져 있다. 전형적인 임상증상
Fig. 2. Sanger sequencing showing p.Glu1251Gln mutation.
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은 30에서 40대에 발현되기 시작하고, 보행실조, 불분명 발음, 시력 
이상, 사지의 조화운동 불능, 안구 움직임 제한, 인지 장애 등 다양한 
증상의 조합을 특징으로 한다. 본 증례의 환아에서는 exome 
sequencing을 통하여 SPTBN2 (p.Glu1251Gln)의 새로운 이형접합 
돌연변이를 발견하였으며 이것이 SCA5의 원인으로 밝혀졌다. 증례의 
환아는 3년 5개월 때 발달지연을 주소로 본원에 내원하였다. 발달지
연을 평가하기 위해 베일리 발달 검사에서 모든 영역에서 현저한 지연
이 확인되었다. 본원 내원 1년 전 시행한 뇌자기공명영상에서 백샐질
형성장애와 약간의 소뇌 위축이 보였다. 잠재적인 유전질환을 의심하
여 진단 목적으로 전체엑솜염기서열분석을 시행하였고 결과적으로 
SPTBN2의 새로운 이형접합 돌연변이 (p.Glu1251Gln) 가 SCA5의 원
인 돌연변이로 사료된다. 척수소뇌실조에서 유전자의 역할을 명확하
게 규명하기 위해서는 전체엑솜염기서열 분석을 포함한 다양한 방법
을 통한 유전자 연구가 필요할 것으로 사료된다. 
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